CAND1

Cullin-associated NEDD8-dissociated protein 1 · Q86VP6 · CAND1 on Sugi Atlas →

0 patent compounds predicted against CAND1, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to CAND1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients PHASE4NOT_YET_RECRUITING
Early Treatment With Candesartan vs Placebo in Genetic Carriers of Dilated Cardiomyopathy (EARLY-GENE Trial) PHASE3RECRUITING
Can We Achieve 'high-quality' Weight Loss Through Supplementation and Exercise? the TRIM MUSCLE Study PHASE3COMPLETED
A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy PHASE3COMPLETED
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers PHASE2NOT_YET_RECRUITING
Safety and Efficacy Study of Small Interfering RNA Molecule (Cand5) to Treat Diabetic Macular Edema PHASE2COMPLETED
Phase II Study of Vandetanib in Individuals With Kidney Cancer PHASE2COMPLETED
A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma PHASE2WITHDRAWN
A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma PHASE2ACTIVE_NOT_RECRUITING
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM) PHASE2RECRUITING
Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only) PHASE1COMPLETED
This is an Open-label, Single Arm Study to Evaluate the Safety and Tolerability of Treatment With CT0591CP in Patients With Relapsed and/or Refractory Multiple Myeloma. EARLY_PHASE1UNKNOWN
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors nanNOT_YET_RECRUITING
The Genetics of Chiari Type I Malformation nanCOMPLETED
Neurocognition in Congenital Central Hypoventilation Syndrome (CCHS) nanRECRUITING
Study of Proteins in Head and Neck Cancer Cells nanCOMPLETED
Quantitative Assessment of the Etiologies of Megalencephaly Associated With a Detectable Tumor Risk nanNOT_YET_RECRUITING
PCM1-JAK2 in Therapy Related Neoplasms nanUNKNOWN
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA nanRECRUITING
Characterization of Angelman Syndrome nanCOMPLETED
Corpus Callosum Agenesis and Intellectual Disability nanCOMPLETED
Angelman Syndrome Natural History Study nanRECRUITING
Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC) nanUNKNOWN
The Role of RING Ubiquitin Ligases in Biologic and Oncologic Processes in Tissues of Mesenchymal Origin nanUNKNOWN
Gene Mutations and Rescue in Human Congenital Diaphragmatic Hernia nanUNKNOWN
Establishment of a Prospective Clinical-biological Database nanRECRUITING
Protein Expression as a Potential Diagnostic Biomarker of Cervical Dysplasia and/or Cancer nanCOMPLETED
Pathogenetic Basis of Aortopathy and Aortic Valve Disease nanACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a CAND1 binder may also engage these)

ProteinNameSimilarity
P97536 1.000 P97536 →
A7MBJ5 1.000 A7MBJ5 →
Q6ZQ38 1.000 Q6ZQ38 →
Q5R6L5 1.000 Q5R6L5 →
Q9VKY2 0.987 Q9VKY2 →
Q9JLN9 0.983 Q9JLN9 →
E9Q912 0.982 E9Q912 →
Q6A026 0.982 Q6A026 →
IPO5 Importin-5 0.982 landscape →
O35643 0.980 O35643 →
P42346 0.980 P42346 →
Q4VA53 0.980 Q4VA53 →
Q5R6J0 0.980 Q5R6J0 →
Q5F3U9 0.980 Q5F3U9 →
Q6TRW4 0.980 Q6TRW4 →
PDS5A Sister chromatid cohesion protein PDS5 homolog A 0.980 landscape →
MTOR Serine/threonine-protein kinase mTOR 0.980 landscape →
Q8BKC5 0.979 Q8BKC5 →
A1L1F4 0.978 A1L1F4 →
Q08DS7 0.978 Q08DS7 →
ECPAS Proteasome adapter and scaffold protein ECM29 0.978 landscape →
A4L9P7 0.978 A4L9P7 →
Q5F3V3 0.978 Q5F3V3 →
Q498H0 0.977 Q498H0 →
P63009 0.977 P63009 →
Q9CRT8 0.977 Q9CRT8 →
P62944 0.976 P62944 →
AP2B1 AP-2 complex subunit beta 0.976 landscape →
Q9GM44 0.976 Q9GM44 →
Q9I8E6 0.976 Q9I8E6 →